AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8452386 — intervention group
Group type: EXPERIMENTAL
Intervention: l-leucovorin 250 mg/m2 weekly
Number of subjects: 0
Study 8452386 — intervention group
Group type: COMPARATOR
Intervention: l-leucovorin 100 mg/m2 for 5 consecutive days
Number of subjects: 0
Study 8452386 — intervention group
Group type: COMPARATOR
Intervention: l-leucovorin 10 mg/m2 for 5 consecutive days
Number of subjects: 0
Study 3512663 — intervention group
Group type: EXPERIMENTAL
Intervention: Slo-bid capsules
Number of subjects: 20
Study 3512663 — intervention group
Group type: COMPARATOR
Intervention: Theo-Dur tablets
Number of subjects: 20
Study 31745223 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 0
Study 31745223 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study 30403730 — intervention group
Group type: EXPERIMENTAL
Intervention: Josamycin
Number of subjects: 1043
Study 30403730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1043
Study 27604334 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-Lyte 148 (PL-148)
Number of subjects: 69
Study 27604334 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 69
Study 24648266 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone turnover biomarkers (serum bone‐specific alkaline phosphatase (BALP), osteocalcin (OC), urinary N‐telopeptide of type I collagen indexed to creatinine (NTX/Cr))
Number of subjects: 418
Study 24648266 — intervention group
Group type: COMPARATOR
Intervention: ALL-related treatments
Number of subjects: 418
Study 24648266 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone turnover
Number of subjects: 418
Study 22674095 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic measurement of intercommissural diameter (EBRS group, n = 43)
Number of subjects: 86
Study 22674095 — intervention group
Group type: COMPARATOR
Intervention: Height-based balloon reference sizing (HBRS group, n = 43)
Number of subjects: 86
Study 20979455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Norwalk VLP vaccine (100-μg dosage)
Number of subjects: 0
Study 20979455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Norwalk VLP vaccine (50-μg dosage)
Number of subjects: 0
Study 20979455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Norwalk VLP vaccine (50-μg and 100-μg dosages)
Number of subjects: 0
Study 20979455 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18568841 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 30
Study 18568841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16026659 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to rest or take it easy
Number of subjects: 71
Study 16026659 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice
Number of subjects: 71
Study 16026659 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice on simple symptom management
Number of subjects: 71
Study 16026659 — intervention group
Group type: EXPERIMENTAL
Intervention: No specific advice
Number of subjects: 71
Study 11951579 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% ibuprofen cream (Dolgit cream), applied in a 10-cm strip t.i.d. for 7 days, each strip containing approximately 200 mg ibuprofen.
Number of subjects: 100
Study 11951579 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream, applied in the same manner as the ibuprofen cream.
Number of subjects: 100
Study 11951579 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary endpoints including pain at rest, pain on pressure, Lequesne index, and overall assessment.
Number of subjects: 100
Study 9686453 — intervention group
Group type: EXPERIMENTAL
Intervention: Equal status - different dimensions condition
Number of subjects: 6
Study 9686453 — intervention group
Group type: EXPERIMENTAL
Intervention: Common in-group identity model
Number of subjects: 6
Study 8090332 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 1 alpha-hydroxycholecalciferol (80 ng/kg body wt)
Number of subjects: 0
Study 8090332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 1 alpha-hydroxycholecalciferol (80 ng/kg body wt)
Number of subjects: 0
Study 8090332 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and intravenous 1 alpha-hydroxycholecalciferol (80 ng/kg body wt)
Number of subjects: 0
Study 8090332 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and intraperitoneal 1 alpha-hydroxycholecalciferol (80 ng/kg body wt)
Number of subjects: 0
Study 8090332 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral, intraperitoneal, and intravenous 1 alpha-hydroxycholecalciferol (80 ng/kg body wt)
Number of subjects: 0
Study 2638641 — intervention group
Group type: EXPERIMENTAL
Intervention: Econazole (1% hair-shampoo)
Number of subjects: 70
Study 2638641 — intervention group
Group type: COMPARATOR
Intervention: Zinc-pyrithione shampoo
Number of subjects: 70
Study 51188 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis-B immunoglobulin
Number of subjects: 0
Study 51188 — intervention group
Group type: COMPARATOR
Intervention: Normal human immunoglobulin (Control)
Number of subjects: 0
Study 31571522 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha‐hydroxyprogesterone caproate (17P)
Number of subjects: 0
Study 30912719 — intervention group
Group type: EXPERIMENTAL
Intervention: CT examinations with intravenous contrast agent (n = 4263)
Number of subjects: 20374
Study 30912719 — intervention group
Group type: COMPARATOR
Intervention: CT examinations without intravenous contrast agent (n = 16,111)
Number of subjects: 20374
Study 30912719 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully automated L1 Hounsfield unit measurement (n = 11,270)
Number of subjects: 20374
Study 30912719 — intervention group
Group type: COMPARATOR
Intervention: Manual L1 Hounsfield unit measurement (n = 9104)
Number of subjects: 20374
Study 28820930 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive strabismus surgery (MISS)
Number of subjects: 40
Study 28820930 — intervention group
Group type: COMPARATOR
Intervention: Conventional strabismus surgery (limbal technique)
Number of subjects: 40
Study 28820930 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 25933487 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with 900 mg of eicosapentaenoic acid plus 680 mg of docosahexaenoic acid for 4 weeks
Number of subjects: 80
Study 24156966 — intervention group
Group type: EXPERIMENTAL
Intervention: pPCI + RIPC (n = 50)
Number of subjects: 100
Study 24156966 — intervention group
Group type: COMPARATOR
Intervention: Conventional pPCI (n = 50)
Number of subjects: 100
Study 24156966 — intervention group
Group type: EXPERIMENTAL
Intervention: pPCI + RIPC
Number of subjects: 100
Study 24156966 — intervention group
Group type: COMPARATOR
Intervention: Conventional pPCI
Number of subjects: 100
Study 22091574 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg
Number of subjects: 16
Study 22091574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19748293 — intervention group
Group type: EXPERIMENTAL
Intervention: IANB plus buccal infiltration (BI)
Number of subjects: 57
Study 19748293 — intervention group
Group type: EXPERIMENTAL
Intervention: IANB plus periodontal ligament (PDL) injection
Number of subjects: 57
Study 17014554 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper extremity AVF
Number of subjects: 30
Study 17014554 — intervention group
Group type: COMPARATOR
Intervention: Non-AVF upper extremity (control)
Number of subjects: 30
Study 15183026 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10763910 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine hydrochloride therapy plus a low energy diet (5040 kJ/d)
Number of subjects: 47
Study 8973780 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine-based treatment
Number of subjects: 1965
Study 8973780 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker (atenolol)-based treatment
Number of subjects: 1965
Study 1611652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil (administered once daily for ten days)
Number of subjects: 0
Study 1611652 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (administered three times a day for ten days)
Number of subjects: 0
Study 1611652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil
Number of subjects: 0
Study 1611652 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 0
Study 1611652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil and Cefaclor
Number of subjects: 0
Study 6142351 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dose of metaraminol infusion
Number of subjects: 21
Study 6142351 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic colchicine therapy
Number of subjects: 21
Study 6142351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29099978 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP (4 pmol × kg‐1 × min‐1) during low glycemia
Number of subjects: 10
Study 29099978 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) during low glycemia
Number of subjects: 10
Study 29099978 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP (4 pmol × kg‐1 × min‐1) during high glycemia
Number of subjects: 10
Study 29099978 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) during high glycemia
Number of subjects: 10
Study 29099978 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP (4 pmol × kg‐1 × min‐1) after 60 minutes
Number of subjects: 10
Study 29099978 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) after 60 minutes
Number of subjects: 10
Study 28288977 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence
Number of subjects: 5966
Study 28288977 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate risk
Number of subjects: 5966
Study 28288977 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk
Number of subjects: 5966
Study 28288977 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high risk
Number of subjects: 5966
Study 28288977 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 5966
Study 28288977 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 5966
Study 28288977 — intervention group
Group type: EXPERIMENTAL
Intervention: Low risk
Number of subjects: 5966
Study 28288977 — intervention group
Group type: EXPERIMENTAL
Intervention: Major CVD events
Number of subjects: 5966
Study 25767259 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK‐1614235 (20 mg) premeal dosing
Number of subjects: 12
Study 25767259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23795579 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina heads
Number of subjects: 39
Study 23795579 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chrome heads
Number of subjects: 39
Study 21259280 — intervention group
Group type: EXPERIMENTAL
Intervention: Early and intensive statin therapy (60 mg immediately and 40 mg/day atorvastatin)
Number of subjects: 586
Study 21259280 — intervention group
Group type: COMPARATOR
Intervention: Conventional statin therapy (10 mg/day atorvastatin)
Number of subjects: 586
Study 19178799 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulante for 3 weeks after FESS
Number of subjects: 71
Study 19178799 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic after FESS (Control group)
Number of subjects: 71
Study 16618013 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg DHEC (Almirid 40 mg test T)
Number of subjects: 24
Study 16618013 — intervention group
Group type: COMPARATOR
Intervention: 2 x 20 mg DHEC (Almirid 20 mg reference R)
Number of subjects: 24
Study 12740740 — intervention group
Group type: EXPERIMENTAL
Intervention: Shot putter 2
Number of subjects: 3
Study 12740740 — intervention group
Group type: EXPERIMENTAL
Intervention: Shot putter 1
Number of subjects: 3
Study 12740740 — intervention group
Group type: COMPARATOR
Intervention: Untrained brother of shot putter 1
Number of subjects: 3
Study 12740740 — intervention group
Group type: EXPERIMENTAL
Intervention: Shot putter 1 after 3 years of active detraining
Number of subjects: 3
Study 10576464 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (10 to 40 mg daily)
Number of subjects: 26
Study 10576464 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (10 to 40 mg daily)
Number of subjects: 26
Study 8963838 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 71
Study 8963838 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 71
Study 8963838 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal carcinomatosis
Number of subjects: 71
Study 8963838 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative cytology
Number of subjects: 71
Study 1724577 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (high dose)
Number of subjects: 20
Study 1724577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6359887 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (a beta 1‐adrenergic antagonist)
Number of subjects: 17
Study 6359887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6359887 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous terbutaline
Number of subjects: 17
Study 6359887 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 17
Study 6359887 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose terbutaline
Number of subjects: 17
Study 6359887 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion dosages above 40 micrograms/min
Number of subjects: 17
Study 6359887 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined beta‐mimetics and glucocorticoids
Number of subjects: 17
Study 3890795 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Penicillamine
Number of subjects: 74
Study 3890795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 30318973 — intervention group
Group type: EXPERIMENTAL
Intervention: Average MVPA per day
Number of subjects: 807
Study 30318973 — intervention group
Group type: COMPARATOR
Intervention: MVPA assessed over 7 days
Number of subjects: 807
Study 26513581 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D bone models
Number of subjects: 58
Study 25006120 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine + volasertib (LDAC + volasertib)
Number of subjects: 87
Study 25006120 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cytarabine (LDAC)
Number of subjects: 87
Study 23271080 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 PRBC/FFP transfusion strategy
Number of subjects: 0
Study 23271080 — intervention group
Group type: COMPARATOR
Intervention: 4:1 PRBC/FFP transfusion strategy
Number of subjects: 0
Study 19825870 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex ultrasound scanning (DUS)
Number of subjects: 59
Study 19825870 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography angiography (CTA)
Number of subjects: 59
Study 18072875 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg of calcium citrate daily (500 mg with meals)
Number of subjects: 14
Study 18072875 — intervention group
Group type: COMPARATOR
Intervention: 250 mg of calcium citrate daily
Number of subjects: 14
Study 18072875 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermal calcium loss during exercise
Number of subjects: 14
Study 18072875 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar spine BMD
Number of subjects: 14
Study 16552324 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based screening for diabetes
Number of subjects: 1757
Study 16552324 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based screening for hypertension
Number of subjects: 1757
Study 16552324 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based screening for high cholesterol
Number of subjects: 1757
Study 16552324 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based screening for high-risk individuals for diabetes
Number of subjects: 1757
Study 16552324 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based screening for high-risk individuals for hypertension
Number of subjects: 1757
Study 16552324 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based screening for high-risk individuals for total cholesterol
Number of subjects: 1757
Study 16552324 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based screening for poorly controlled known diabetes
Number of subjects: 1757
Study 16552324 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based screening for poorly controlled known hypertension
Number of subjects: 1757
Study 16552324 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based screening for poorly controlled known high cholesterol
Number of subjects: 1757
Study 12970287 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d (RLX60)
Number of subjects: 64
Study 12970287 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/d (RLX120)
Number of subjects: 64
Study 12970287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 10792117 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin, 1200 mg/day (400 mg t.d.s.)
Number of subjects: 21
Study 10792117 — intervention group
Group type: COMPARATOR
Intervention: Chlortetracycline, 1 g/day (333 mg t.d.s.)
Number of subjects: 21
Study 9240777 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative mitomycin-C (0.04%) for 2 weeks
Number of subjects: 43
Study 9240777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin-C (0.04%) as a single dose
Number of subjects: 43
Study 9240777 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgical excision only)
Number of subjects: 43
Study 1467256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative learning in small groups
Number of subjects: 594
Study 1467256 — intervention group
Group type: EXPERIMENTAL
Intervention: Specially designed social relations programme
Number of subjects: 594
Study 1467256 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of social relations programme and cooperative learning
Number of subjects: 594
Study 1467256 — intervention group
Group type: COMPARATOR
Intervention: Traditional pedagogical approaches (comparison group)
Number of subjects: 594
Study 6647870 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 0
Study 6647870 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-hydroxyprogesterone caproate
Number of subjects: 0
Study 6647870 — intervention group
Group type: COMPARATOR
Intervention: Untreated women
Number of subjects: 0
Study 30774069 — intervention group
Group type: EXPERIMENTAL
Intervention: DRIFT (drainage, irrigation and fibrinolytic therapy)
Number of subjects: 52
Study 30774069 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (cerebrospinal fluid tapping)
Number of subjects: 52
Study 27903837 — intervention group
Group type: EXPERIMENTAL
Intervention: New fighting vest designed for female body shape
Number of subjects: 240
Study 27903837 — intervention group
Group type: COMPARATOR
Intervention: Standard special unit fighting vest
Number of subjects: 240
Study 26116011 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic antireflux surgery (LARS)
Number of subjects: 67
Study 23530976 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-supervised lower limb muscle strengthening exercises for 10 weeks
Number of subjects: 17
Study 23530976 — intervention group
Group type: COMPARATOR
Intervention: No exercises (control)
Number of subjects: 17
Study 21774100 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention (patient education, home BP monitoring, BP measurement reporting to an IVR system, clinical pharmacist follow-up)
Number of subjects: 338
Study 21774100 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 338
Study 19260949 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 14
Study 19260949 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg daily)
Number of subjects: 14
Study 19260949 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of simvastatin and bezafibrate
Number of subjects: 14
Study 19260949 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (49 non-diabetic)
Number of subjects: 14
Study 16440534 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 455
Study 16440534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455
Study 15268810 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg once daily for 52 weeks
Number of subjects: 105
Study 11577896 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavelet analysis
Number of subjects: 40
Study 11577896 — intervention group
Group type: COMPARATOR
Intervention: Fourier analysis
Number of subjects: 40
Study 10434907 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative analysis of enhancement patterns using T1 weighted spoiled gradient recalled echo (SPGR) images during bolus intravenous injection of 0.1 mmol kg‐1 of Gd‐chelate
Number of subjects: 32
Study 10434907 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer assisted analysis
Number of subjects: 32
Study 10434907 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual measurements of maximum enhancement
Number of subjects: 32
Study 10434907 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of maximum enhancement alone
Number of subjects: 32
Study 7805462 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril plus spironolactone
Number of subjects: 35
Study 7805462 — intervention group
Group type: COMPARATOR
Intervention: Captopril alone
Number of subjects: 35
Study 3292516 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 41
Study 3292516 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 41
Study 3292516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 31340917 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration of ropivacaine combined with multimodal analgesia with parecoxib
Number of subjects: 98
Study 31340917 — intervention group
Group type: COMPARATOR
Intervention: Postoperative analgesia with dizosin
Number of subjects: 98